modelR03DA05_1
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Aminophylline_1 | |
| ATC code: | R03DA05_1 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 0.7 | L |
| clearance: | 0.07 | L/kg/h |
| other parameters in model implementation | ||
Aminophylline is a bronchodilator consisting of theophylline and ethylenediamine, used in the management of asthma, chronic obstructive pulmonary disease (COPD), and sometimes apnea of prematurity. It is administered orally or intravenously, though its use has declined due to the availability of newer agents. Aminophylline is still approved and used in certain clinical contexts.
Pharmacokinetics
PK parameters reported in children with asthma after intravenous administration.
References
Moore, ES, et al., & Grasela, TH (1989). The population pharmacokinetics of theophylline in neonates and young infants. Journal of pharmacokinetics and biopharmaceutics 17(1) 47–66. DOI:10.1007/BF01059087 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2715932
Frymoyer, A, et al., & Chock, VY (2020). Theophylline dosing and pharmacokinetics for renal protection in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. Pediatric research 88(6) 871–877. DOI:10.1038/s41390-020-01140-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32919393
Park, K, et al., & Halstead, ES (2018). No Requirement for Targeted Theophylline Levels for Diuretic Effect of Aminophylline in Critically Ill Children. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 19(8) e425–e432. DOI:10.1097/PCC.0000000000001608 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29927879
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)